| Officer | Age | In this role | Joined | 2024 pay | Source |
|---|---|---|---|---|---|
|
Ilan Hadar
Also a director
Chairman and Chief Executive Officer
|
56 | Not stated | Not stated | $1,540,628 | |
|
Mirit Horenshtein Hadar
Chief Financial Officer and Secretary
|
42 | Not stated | 2024 | $770,090 | |
|
Mitchell Shirvan
Chief Scientific and Development Officer
|
72 |
Since 2022
4 years
|
2022 | $1,301,490 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Employment agreement with wholly-owned subsidiary Silexion Israel providing monthly salary, annual base salary, and benefits
Employment agreement with wholly-owned subsidiary Silexion Israel providing monthly salary, annual base salary, and benefits
Employment agreement with Silexion Israel providing monthly salary, annual base salary, and benefits
Indemnification agreements providing indemnification and advancement of expenses
Purchase of 1,482 newly issued Moringa ordinary shares in PIPE Financing
Customary registration rights for resale of PIPE Shares
Amended and restated sponsor promissory note
Conversion of $1.8 million of sponsor promissory note into 450,000 ordinary shares
Amended and restated registration rights and lock-up agreement
January 2025 warrant exercise inducement transaction
July/August 2025 warrant exercise inducement transaction
Loading...
